Pursuant to the provisions of Regulation 30 and other applicable provisions, if any, of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Procter & Gamble Health has informed that the Company plans to source injections portfolio of its products from a contract manufacturer, hence the Company shall discontinue production of injections at its manufacturing plant in Goa effective September 30, 2023. The injections portfolio, procured from the Company’s manufacturing facility at Goa, accounted for revenue of Rs 102.92 crores during the financial year 2022-23, constituting 8.37% of the Company’s total revenue. Discontinuation of production at Company’s plant in Goa, shall not have an impact on continuity of sale of injections by the Company, as the products will be sourced from a contract manufacturer. The Company is outsourcing manufacturing of the injection’s portfolio, with an intent to achieve cost efficiency and supply optimization.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1820.50 |
| Dr. Reddys Lab | 1301.00 |
| Cipla | 1332.80 |
| Zydus Lifesciences | 901.30 |
| Lupin | 2350.30 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: